Neurocrine Biosciences agreed to acquire Soleno Therapeutics for about $2.9 billion, securing ownership of Vykat — the only approved treatment for the life‑threatening hyperphagia that characterizes Prader‑Willi syndrome. The offer, announced Monday, values Soleno at $53 a share, a roughly 34% premium to the company’s closing price on the prior Thursday.
Vykat received U.S. regulatory approval in March 2025 to treat hyperphagia in patients with Prader‑Willi syndrome, a rare genetic disorder marked by insatiable appetite, risk of severe obesity and related complications. Soleno’s drug is currently the sole marketed therapy specifically for hyperphagia in this population, giving its owner exclusive commercial rights in a niche but clinically urgent area of rare‑disease care.
The deal gives Neurocrine immediate access to Vykat’s approved label and any existing commercialization infrastructure Soleno has put in place since last year’s approval. Neurocrine did not disclose further financial arrangements in the announcement beyond the per‑share consideration and the transaction’s headline value. The $53 per‑share offer reflects a significant premium for Soleno investors compared with the company’s recent trading level.
Prader‑Willi syndrome is a lifelong condition that typically appears in early childhood and can include developmental delays and endocrine abnormalities in addition to hyperphagia. The relentless hunger associated with the syndrome is widely regarded as one of its most dangerous symptoms, driving high unmet medical need and prompting intensive clinical and regulatory focus on therapeutic options. Vykat’s approval last year marked the first time regulators cleared a drug specifically to address this symptom in Prader‑Willi patients.
Industry analysts and investors will be watching how Neurocrine integrates Vykat into its portfolio and whether the company moves to expand the drug’s label or pursue broader geographic approvals. For families and caregivers, Neurocrine’s acquisition could mean changes in distribution, patient support programs and pricing strategies, depending on how the new owner commercializes the therapy.
The transaction is the latest sizable move in the rare‑disease and specialty‑pharma M&A landscape, where larger firms often buy small companies with approved products to accelerate commercial scale or diversify portfolios. With a marketed, first‑in‑class treatment in hand, Neurocrine steps into a distinct position within the Prader‑Willi therapeutic space. Further details on the timeline for closing the acquisition, any regulatory approvals required for the deal itself, and post‑transaction plans were not disclosed in Monday’s announcement.